Freshfields Bruckhaus Deringer represented Sumitovant Biopharma Limited. On January 30, 2025, the Second Circuit affirmed the District Court’s dismissal with prejudice of a putative Section 14(a)...
Sumitovant Biopharma Limited v. Myovant Sciences Limited
Zappia v. Myovant Sciences Ltd., et al.
Freshfields’ Litigation Team successfully represented Sumitovant Biopharma Limited. A shareholder’s attempt to challenge a $2.9 billion take-private merger between Sumitovant Biopharma Limited (Sumitovant, formerly known as...